April 2016

Advocacy Drives Medical Progress Forward

Paul Carey Jr. advocating for ALS Research on Capitol Hill Twelve years ago on Friday the 13th, Lorri Carey's life changed forever. Her neurologist asked during one of her appointments "what do you know about ALS (amyotrophic lateral sclerosis)?"

A Study to Evaluate the Performance of a Diagnostic Test in ALS

Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention: Procedure: Lumbar puncture
Sponsor: Iron Horse Diagnostics, Inc.
Recruiting - verified April 2016

Future brain therapies for Parkinson's possible with stem cell bioengineering innovation

This may eventually help people suffering from Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), or Lou Gehrig ... cells that you're now transplanting,” said Moghe, research director for the School of Engineering/Health ...

AB Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis (ALS)

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization ... evaluating masitinib in the treatment of amyotrophic lateral sclerosis has met its primary objective.

Synthetic Biologics Inc (SYN) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Synthetic Biologics ... cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered ...

Zacks Investment Research Lowers Synthetic Biologics Inc (SYN) to Hold

Zacks Investment Research cut shares of Synthetic Biologics Inc (NYSE ... cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is ...

Synthetic Biologics Inc (SYN) Downgraded by Zacks Investment Research to Hold

Synthetic Biologics Inc (NYSE:SYN) was downgraded by Zacks Investment Research from a “buy ... relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc ...

April 2016

Advocacy Drives Medical Progress Forward

A Study to Evaluate the Performance of a Diagnostic Test in ALS

Future brain therapies for Parkinson's possible with stem cell bioengineering innovation

AB Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis (ALS)

Synthetic Biologics Inc (SYN) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research Lowers Synthetic Biologics Inc (SYN) to Hold

Synthetic Biologics Inc (SYN) Downgraded by Zacks Investment Research to Hold

Pages

Keep in touch

Be a team player

Learn about ALS

Get help

You are here

April 2016

Pages

Keep in touch

Be a team player

Learn about ALS

Get help